## Understanding K. phaffii (Pichia pastoris) Host Cell Proteins: Proteomic Analysis and Flow-through Affinity Clearance

Sobhana Alekhya Sripada<sup>1</sup>, Driss Elhanafi<sup>2</sup>, Leonard Collins<sup>3</sup>, Taufika Islam Williams<sup>3</sup>, Marina Linova<sup>4</sup>, John Woodley<sup>4</sup>, and Stefano Menegatti<sup>1</sup>

<sup>1</sup>NC State University Department of Chemical and Biomolecular Engineering
<sup>2</sup>NC State University
<sup>3</sup>NC State University Department of Chemistry
<sup>4</sup>Danmarks Tekniske Universitet


February 1, 2023


## Abstract


K. phaffii is a versatile expression system that is increasingly utilized to produce biological therapeutics – including enzymes, engineered antibodies, and gene-editing tools – that feature multiple subunits and complex post-translational modifications. Two major roadblocks limit the adoption of K. phaffii in industrial biomanufacturing: its proteome, while known, has not been linked to downstream process operations and detailed knowledge is missing on problematic host cell proteins (HCPs) that endanger patient safety or product stability; furthermore, the purification toolbox has not evolved beyond the capture of monospecific antibodies, and few solutions are available for engineered antibody fragments and other protein therapeutics. To unlock the potential of yeast-based biopharmaceutical manufacturing, this study presents (i) a secretome survey of K. phaffii cell culture harvests that highlights HCPs with predicted immunogenicity, ability to cause product association or co-elution; and (ii) a novel affinity adsorbent functionalized with peptide ligands that target the whole spectrum of K. phaffii HCPs – PichiaGuard – designed for the enrichment of therapeutic proteins in flow-through mode. The PichiaGuard adsorbent features high HCP binding capacity (~25 g per liter of resin) and successfully purified a monoclonal antibody and an ScFv fragment from clarified K. phaffii harvests, affording up to 80% product yield, and a >300-fold removal of HCPs. Notably, PichiaGuard outperformed commercial ion exchange and mixed-mode resins in removing high-risk HCPs – including aspartic proteases, ribosomal subunits, and other peptidases – thus demonstrating its value in modern biopharmaceutical processing.


## Hosted file


PichiaGuard\_SAS\_Manuscript.docx available at https://authorea.com/users/453928/articles/ 622232-understanding-k-phaffii-pichia-pastoris-host-cell-proteins-proteomic-analysisand-flow-through-affinity-clearance


















(D)









(A) (C) ...... ..... -tipe int Acetate Phosph ······ (B) ..... 1111111111111111 ..... . ..... ..... 0 - CHENT FTF FT (A) (B) (C) mAb ScFv13R4 Chas Chase HCP cLRV 0a0 mAb 1.18 250 150 100 75 50 37 .....

## Hosted file

PichiaGuard\_SAS\_Figures.pptx available at https://authorea.com/users/453928/articles/622232understanding-k-phaffii-pichia-pastoris-host-cell-proteins-proteomic-analysis-and-flowthrough-affinity-clearance